Skip to main content
Clinical Trials/NCT03771612
NCT03771612
Completed
Early Phase 1

Inflammation and Daily Life Study

University of California, Los Angeles1 site in 1 country144 target enrollmentFebruary 9, 2022
ConditionsInflammation
InterventionsNaproxenPlacebos

Overview

Phase
Early Phase 1
Intervention
Naproxen
Conditions
Inflammation
Sponsor
University of California, Los Angeles
Enrollment
144
Locations
1
Primary Endpoint
Loneliness
Status
Completed
Last Updated
last year

Overview

Brief Summary

UCLA researchers looking for healthy individuals (age 45-60) to participate in a study investigating whether an anti-inflammatory medication can impact daily life experiences.

Everyday for two weeks, participants will take either an anti-inflammatory medication (naproxen) twice daily, or a placebo pill twice daily. Participants will also answer daily questions during the 2-week period. Participants will also fill out questionnaires and complete a few tasks on the computer: once prior to the 2-week period and once immediately after the 2-week period, both during online study sessions.

Detailed Description

Participants (ntotal=50) will be men and women, ages 45-60. All interested participants will first complete a structured telephone interview in order to assess eligibility. The study will begin with filling out questionnaires, as well as an online session to complete some tasks. You will then be randomly assigned to take either an anti-inflammatory medication (naproxen) or placebo (inactive substance) to take twice daily everyday for the following two weeks. You will also be contacted by text message to remind you to take your pills, to ask if you have taken your pills, and to send you a link to fill out questionnaires once daily. After the two weeks are over, you will again complete questionnaires and the online study session with tasks. Finally, two weeks after the second session, you will receive an email to fill out questionnaires online.

Registry
clinicaltrials.gov
Start Date
February 9, 2022
End Date
June 21, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Naomi Eisenberger

Professor

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • healthy adults 45-60

Exclusion Criteria

  • Following a structured telephone interview, participants with the following conditions will not be able to participate:
  • certain active, uncontrolled medical disorders
  • use of certain medications (e.g., hypnotic and psychotropic medication, steroid use, opioid use)
  • psychiatric disorders (e.g., current major depression, bipolar disorder)
  • Other exclusion criteria may apply.

Arms & Interventions

Naproxen

Intervention: Naproxen

Placebo

Intervention: Placebos

Outcomes

Primary Outcomes

Loneliness

Time Frame: T1: Baseline, T2: post-intervention (2 weeks later)

Changes in self-report measures of loneliness (University of California, Los Angeles (UCLA) Loneliness Scale) Scale ranges from 20-80 (though participants were included based on higher levels of loneliness, \> 41). Higher values represent higher levels of loneliness.

Negative Picture Viewing Task

Time Frame: T1: Baseline, T2: post-intervention (2 weeks later)

Changes in ratings of negative pictures "To what extent is this picture positive or negative: from -5 (very negative) to +5 (very positive)" Lower scores indicate more negativity

Social Reward Task

Time Frame: T1: Baseline, T2: post-intervention (2 weeks later)

Changes in reaction time to close others vs. control image (measures in seconds) Faster reaction times indicate greater sensitivity; so lower scores (fewer seconds) indicate greater sensitivity to close others vs. control images

Secondary Outcomes

  • Inflammatory Gene Expression(T1: Baseline, T2: post-intervention (2 weeks later))
  • Loneliness at Follow-up (2 Weeks Post-intervention)(T3: 2 weeks after the end of the intervention (4 weeks after the start of the intervention))

Study Sites (1)

Loading locations...

Similar Trials